Nama's AI scorecard currently rates Iovance Biotherapeutics Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does IOVA report earnings?

Iovance Biotherapeutics's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$0.05.

What is the IOVA price target?

The median analyst price target from 10 analysts is $15.50, with a range of $8.00 – $20.00.

Is IOVA Shariah compliant?

Nama's AAOIFI-style screen reads Iovance Biotherapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Iovance Biotherapeutics (IOVA)

Healthcare · Biotechnology · NASDAQ

Iovance Biotherapeutics (IOVA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.64B and a free-cash-flow yield of -11.7%. Over the most recent reported fiscal year, revenue grew 60.6%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Hold · 4.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Leading · +459.1% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-69.2%

How far the last close sits under the highest price of the past five years.

Market cap	$3.64B
Trailing P/E	—
Price / book	5.0
Price / sales	11.2
FCF yield	-11.7%
Dividend yield	—
Gross margin	48.4%
Operating margin	-91.1%
Net margin	-89.1%
Revenue growth (YoY)	+60.6%
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

IOVA earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate -$0.05). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	-$0.05	-$0.09	+44.4%	—
Q2 2026	Aug 6, 2026	-$0.11	-$0.13	+15.4%	$99.31M
Q1 2026	May 7, 2026	-$0.19	-$0.15	-26.7%	$71.43M
Q4 2025	Feb 24, 2026	-$0.18	-$0.18	+0.0%	$86.77M

IOVA analyst price target

Median target $15.50 from 10 analysts, ranging $8.00 – $20.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live IOVA data on Nama Insights →

IOVA FAQ

Is IOVA a buy?: Nama's AI scorecard currently rates Iovance Biotherapeutics Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does IOVA report earnings?: Iovance Biotherapeutics's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$0.05.
What is the IOVA price target?: The median analyst price target from 10 analysts is $15.50, with a range of $8.00 – $20.00.
Is IOVA Shariah compliant?: Nama's AAOIFI-style screen reads Iovance Biotherapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.